ERCC1预测晚期非小细胞肺癌患者铂类化疗敏感性的临床研究  

Study on the Expression of ERCC1 and Prediction of Platinum-based Chemotherapy Sensitivity in Advanced Non-Small Cell Lung Cancer

作　　者：郑玲[1] 伍建蓉[1] 白娟[1] 李佽[1] 谷焰[1] 王晓毓[1] 刘都礼[1] 

机构地区：[1]成都大学附属医院肿瘤科,610081

出　　处：《实用癌症杂志》2013年第1期38-41,共4页The Practical Journal of Cancer

摘　　要：目的探讨切除修复交叉互补基因1(ERCC1)表达与非小细胞肺癌患者化疗疗效的关系。方法采用免疫组织化学法,检测103例Ⅲ期、Ⅳ期非小细胞肺癌患者中ERCC1表达情况,分析化疗疗效,并作生存分析。结果 103例晚期非小细胞肺癌患者中ERCC1阳性表达率为46.6%(48/103),其与患者年龄、性别、肿瘤病理类型及临床分期无关(P>0.05)。第1组[ERCC1(+)TP组]:ERCC1阳性表达者采用TP化疗方案;第2组[ERCC1(+)GP组]ERCC1阳性表达者采用GP化疗方案;第3组[ERCC1(-)TP组]ERCC1阴性表达者采用TP化疗方案;第4组[ERCC1(-)TP组]ERCC1阴性表达者采用GP化疗方案。第1、2、3、4组临床有效率分别为16.7%(4/24)、50.0%(12/24)、52.0%(13/25)和33.3%(10/30),第1组与第3组疗效比较,有统计学意义(P<0.05);第2组化疗有效率为50.0%,与第3组和第4组疗效相当(52.0%和33.3%),差异无统计学意义。生存分析显示,4组总体生存曲线相同,χ2=1.3589,P=0.7152,P>0.05,无显著性差异。结论 ERCC1阳性表达的非小细胞肺癌患者对铂类耐药,吉西他滨能提高铂类耐药患者的化疗有效率。Objective To determine the correlation of ERCC1 with advanced non-small cell lung cancer（NSCLC）.Methods The expression of ERCC1 was examined by immuno-histochemical technique in 103 patients with advance non-small-cell lung cancer.The data of therapeutical effect were collected and analyzed,and the survival analysis was conducted.Results The expression of ERCC1 was 46.6% among 103 cases,and there was no correlation with patient age,clinical stage,pathology type and gender;The patients were divided into four groups.Patients in 1st group（n=24）had positive ERCC1 expression and received paclitaxel plus cisplatin chemotherapy（TP）;Patients in 2nd group（n=24） had positive ERCC1 expression and received gemcitabine plus cisplatin chemotherapy（GP）;Patients in 3rd（n=25）had negative ERCC1 expression and received paclitaxel plus cisplatin chemotherapy（TP）;Patients in 4th group（n=30） had negative ERCC1 expression and received gemcitabine plus cisplatin chemotherapy（GP）;The response rates of chemotherapy（CR＋PR） in 4 groups were 16.7%,50.0%,52.0%,33.3%,respectively.There was significant difference in the response rate between group 1 and group 2（P0.05）;The response rate in group 2 was similar with these of group 3 and group 4,there was no remarkable difference compared（P0.05）.The survival analysis shows that four groups there were no statistical differences in the 4 groups（χ2=1.3589,P=0.7152）.Conclusion The expression of ERCC1 was related to platinum-based chemotherapy sensitivity and could predict platinum-based chemotherapy sensitivity in advanced non-small-cell lung cancer.Genotypic make and adjust the competence of ERCC1 expression and improve the sensitivity of platinum-based chemotherapy.

关 键 词：非小细胞肺癌 铂类 切除修复交叉互补基因1 

分 类 号：R734.2[医药卫生—肿瘤]